Skip to main content
Top
Published in: Acta Neuropathologica 4/2017

Open Access 01-04-2017 | Original Paper

UK Iatrogenic Creutzfeldt–Jakob disease: investigating human prion transmission across genotypic barriers using human tissue-based and molecular approaches

Authors: Diane L. Ritchie, Marcelo A. Barria, Alexander H. Peden, Helen M. Yull, James Kirkpatrick, Peter Adlard, James W. Ironside, Mark W. Head

Published in: Acta Neuropathologica | Issue 4/2017

Login to get access

Abstract

Creutzfeldt–Jakob disease (CJD) is the prototypic human prion disease that occurs most commonly in sporadic and genetic forms, but it is also transmissible and can be acquired through medical procedures, resulting in iatrogenic CJD (iCJD). The largest numbers of iCJD cases that have occurred worldwide have resulted from contaminated cadaveric pituitary-derived human growth hormone (hGH) and its use to treat primary and secondary growth hormone deficiency. We report a comprehensive, tissue-based and molecular genetic analysis of the largest series of UK hGH-iCJD cases reported to date, including in vitro kinetic molecular modelling of genotypic factors influencing prion transmission. The results show the interplay of prion strain and host genotype in governing the molecular, pathological and temporal characteristics of the UK hGH-iCJD epidemic and provide insights into the adaptive mechanisms involved when prions cross genotypic barriers. We conclude that all of the available evidence is consistent with the hypothesis that the UK hGH-iCJD epidemic resulted from transmission of the V2 human prion strain, which is associated with the second most common form of sporadic CJD.
Appendix
Available only for authorised users
Literature
1.
go back to reference Barria MA, Balachandran A, Morita M, Kitamoto T, Barron R, Manson J et al (2014) Molecular barriers to zoonotic prion transmission. Emerg Infect Dis 20:88–97CrossRefPubMedPubMedCentral Barria MA, Balachandran A, Morita M, Kitamoto T, Barron R, Manson J et al (2014) Molecular barriers to zoonotic prion transmission. Emerg Infect Dis 20:88–97CrossRefPubMedPubMedCentral
2.
go back to reference Bishop MT, Pennington C, Heath CA, Will RG, Knight RSG (2009) PRNP variation in UK sporadic and variant Creutzfeldt-Jakob disease highlights genetic risk factors and a novel non-synonymous polymorphism. BMC Med Genet 10:146CrossRefPubMedPubMedCentral Bishop MT, Pennington C, Heath CA, Will RG, Knight RSG (2009) PRNP variation in UK sporadic and variant Creutzfeldt-Jakob disease highlights genetic risk factors and a novel non-synonymous polymorphism. BMC Med Genet 10:146CrossRefPubMedPubMedCentral
3.
go back to reference Bishop M, Will RG, Manson JM (2010) Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties. Proc Natl Acad Sci USA 107:12005–12010CrossRefPubMedPubMedCentral Bishop M, Will RG, Manson JM (2010) Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties. Proc Natl Acad Sci USA 107:12005–12010CrossRefPubMedPubMedCentral
4.
go back to reference Brandel JP, Preece M, Brown P, Croes E, Laplanche JL, Aquid Y et al (2003) Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK. Lancet 362:128–130CrossRefPubMed Brandel JP, Preece M, Brown P, Croes E, Laplanche JL, Aquid Y et al (2003) Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK. Lancet 362:128–130CrossRefPubMed
5.
go back to reference Brown P, Brandel JP, Sato T, Nakamura Y, MacKenzie J, Will RG et al (2012) Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerg Infect Dis 18:901–907CrossRefPubMedPubMedCentral Brown P, Brandel JP, Sato T, Nakamura Y, MacKenzie J, Will RG et al (2012) Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerg Infect Dis 18:901–907CrossRefPubMedPubMedCentral
6.
go back to reference Cali I, Miller CJ, Parisi JE, Geschwind MD, Gambetti P, Schonberger LB (2015) Distinct pathological phenotypes of Creutzfeldt-Jakob disease in recipients of prion-contaminated growth hormone. Acta Neuropathol Commun 3:37CrossRefPubMedPubMedCentral Cali I, Miller CJ, Parisi JE, Geschwind MD, Gambetti P, Schonberger LB (2015) Distinct pathological phenotypes of Creutzfeldt-Jakob disease in recipients of prion-contaminated growth hormone. Acta Neuropathol Commun 3:37CrossRefPubMedPubMedCentral
7.
go back to reference Collinge J, Clarke AR (2007) A general model for prion strains and their pathogenicity. Science 318:930–936CrossRefPubMed Collinge J, Clarke AR (2007) A general model for prion strains and their pathogenicity. Science 318:930–936CrossRefPubMed
8.
go back to reference Collinge J, Whitfield J, McKintosh E, Frosh A, Mead S, Hill AF et al (2008) A clinical study of kuru patients with long incubation periods at the end of the epidemic in Papua New Guinea. Philos Trans R Soc Lond B Biol Sci 363:3725–3739CrossRefPubMedPubMedCentral Collinge J, Whitfield J, McKintosh E, Frosh A, Mead S, Hill AF et al (2008) A clinical study of kuru patients with long incubation periods at the end of the epidemic in Papua New Guinea. Philos Trans R Soc Lond B Biol Sci 363:3725–3739CrossRefPubMedPubMedCentral
9.
go back to reference Eiden M, Buschmann A, Kupfer L, Groschup MH (2006) Synthetic prions. J Vet Med B Infect Dis Vet Public Health 53:251–256CrossRefPubMed Eiden M, Buschmann A, Kupfer L, Groschup MH (2006) Synthetic prions. J Vet Med B Infect Dis Vet Public Health 53:251–256CrossRefPubMed
10.
go back to reference Gibbs CJ Jr, Joy A, Heffner R, Franko M, Miyazaki M, Asher DM et al (1985) Clinical and pathological features and laboratory confirmation of Creutzfeldt-Jakob disease in a recipient of pituitary-derived human growth hormone. N Engl J Med 313:734–738CrossRefPubMed Gibbs CJ Jr, Joy A, Heffner R, Franko M, Miyazaki M, Asher DM et al (1985) Clinical and pathological features and laboratory confirmation of Creutzfeldt-Jakob disease in a recipient of pituitary-derived human growth hormone. N Engl J Med 313:734–738CrossRefPubMed
11.
go back to reference Gibbs CJ Jr, Asher DM, Brown PW, Fradkin JE, Gajdusek DC (1993) Creutzfeldt-Jakob disease infectivity of growth hormone derived from human pituitary glands. N Engl J Med 328:358–359CrossRefPubMed Gibbs CJ Jr, Asher DM, Brown PW, Fradkin JE, Gajdusek DC (1993) Creutzfeldt-Jakob disease infectivity of growth hormone derived from human pituitary glands. N Engl J Med 328:358–359CrossRefPubMed
12.
go back to reference Head MW, Ironside JW, Ghetti B, Jeffrey M, Piccardo P, Will RW (2015) Prion diseases. In: Love S, Budka H, Ironside JW, Perry A (eds) Greenfield’s Neuropathology, 9th edn. CRC Press, Boca Raton, pp 1016–1086 Head MW, Ironside JW, Ghetti B, Jeffrey M, Piccardo P, Will RW (2015) Prion diseases. In: Love S, Budka H, Ironside JW, Perry A (eds) Greenfield’s Neuropathology, 9th edn. CRC Press, Boca Raton, pp 1016–1086
13.
go back to reference Heath CA, Barker RA, Esmonde TF, Harvey P, Roberts R, Trend P et al (2006) Dura mater-associated Creutzfeldt-Jakob disease: experience from surveillance in the UK. J Neurol Neurosurg Psychiatry 77:880–882CrossRefPubMedPubMedCentral Heath CA, Barker RA, Esmonde TF, Harvey P, Roberts R, Trend P et al (2006) Dura mater-associated Creutzfeldt-Jakob disease: experience from surveillance in the UK. J Neurol Neurosurg Psychiatry 77:880–882CrossRefPubMedPubMedCentral
14.
go back to reference Ironside JW, Knight RSG, Head MW (2011) Iatrogenic Creutzfeldt-Jakob disease. In: Dickson DW, Weller RO (eds) Neurodegeneration: the molecular pathology of dementia and movement disorders, 2nd edn. Wiley-Blackwell, Oxford, pp 381–386CrossRef Ironside JW, Knight RSG, Head MW (2011) Iatrogenic Creutzfeldt-Jakob disease. In: Dickson DW, Weller RO (eds) Neurodegeneration: the molecular pathology of dementia and movement disorders, 2nd edn. Wiley-Blackwell, Oxford, pp 381–386CrossRef
15.
go back to reference Kobayashi A, Asano M, Mohri S, Kitamoto T (2007) Cross-sequence transmission of sporadic Creutzfeldt-Jakob disease creates a new prion strain. J Biol Chem 282:30022–30028CrossRefPubMed Kobayashi A, Asano M, Mohri S, Kitamoto T (2007) Cross-sequence transmission of sporadic Creutzfeldt-Jakob disease creates a new prion strain. J Biol Chem 282:30022–30028CrossRefPubMed
16.
go back to reference Kobayashi A, Sakuma N, Matsuura Y, Mohri S, Aguzzi A, Kitamoto T (2010) Experimental verification of the traceback phenomenon in prion infection. J Virol 84:3230–3238CrossRefPubMedPubMedCentral Kobayashi A, Sakuma N, Matsuura Y, Mohri S, Aguzzi A, Kitamoto T (2010) Experimental verification of the traceback phenomenon in prion infection. J Virol 84:3230–3238CrossRefPubMedPubMedCentral
17.
go back to reference Kobayashi A, Iwasaki Y, Otsuka H, Yamada M, Yoshida M, Matsuura Y et al (2013) Deciphering the pathogenesis of sporadic Creutzfeldt-Jakob disease with codon 129 M/V and type 2 abnormal prion protein. Acta Neuropathol Commun 1:74CrossRefPubMedPubMedCentral Kobayashi A, Iwasaki Y, Otsuka H, Yamada M, Yoshida M, Matsuura Y et al (2013) Deciphering the pathogenesis of sporadic Creutzfeldt-Jakob disease with codon 129 M/V and type 2 abnormal prion protein. Acta Neuropathol Commun 1:74CrossRefPubMedPubMedCentral
18.
go back to reference Kobayashi A, Matsuura Y, Mohri S, Kitamoto T (2014) Distinct origins of dura mater graft-associated Creutzfeldt-Jakob disease: past and future problems. Acta Neuropathol Commun 2:32CrossRefPubMedPubMedCentral Kobayashi A, Matsuura Y, Mohri S, Kitamoto T (2014) Distinct origins of dura mater graft-associated Creutzfeldt-Jakob disease: past and future problems. Acta Neuropathol Commun 2:32CrossRefPubMedPubMedCentral
19.
go back to reference Kobayashi A, Parchi P, Yamada M, Brown P, Saverioni D, Matsuura Y et al (2015) Transmission properties of atypical Creutzfeldt-Jakob disease: a clue to disease etiology. J Virol 98:3939–3946CrossRef Kobayashi A, Parchi P, Yamada M, Brown P, Saverioni D, Matsuura Y et al (2015) Transmission properties of atypical Creutzfeldt-Jakob disease: a clue to disease etiology. J Virol 98:3939–3946CrossRef
20.
go back to reference Kobayashi A, Parchi P, Yamada M, Mohri S, Kitamoto T (2015) Neuropathological and biochemical criteria to identify acquired Creutzfeldt-Jakob disease among presumed sporadic cases. Neuropathol. doi:10.1111/neup.12270 (Epub ahead of print) Kobayashi A, Parchi P, Yamada M, Mohri S, Kitamoto T (2015) Neuropathological and biochemical criteria to identify acquired Creutzfeldt-Jakob disease among presumed sporadic cases. Neuropathol. doi:10.​1111/​neup.​12270 (Epub ahead of print)
21.
go back to reference Moda F, Suardis S, Di Fede G, Indaco A, Limido L, Vimercati C et al (2012) MM2-thalamic Creutzfeldt-Jakob disease: neuropathological, biochemical and transmission studies identify a distinctive prion strain. Brain Pathol 22:662–669CrossRefPubMed Moda F, Suardis S, Di Fede G, Indaco A, Limido L, Vimercati C et al (2012) MM2-thalamic Creutzfeldt-Jakob disease: neuropathological, biochemical and transmission studies identify a distinctive prion strain. Brain Pathol 22:662–669CrossRefPubMed
23.
go back to reference Parchi P, Strammiello R, Notari S, Giese A, Langeveld JP, Ladogana A et al (2009) Incidence and spectrum of sporadic Creutzfeldt-Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: an updated classification. Acta Neuropathol 118:659–671CrossRefPubMedPubMedCentral Parchi P, Strammiello R, Notari S, Giese A, Langeveld JP, Ladogana A et al (2009) Incidence and spectrum of sporadic Creutzfeldt-Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: an updated classification. Acta Neuropathol 118:659–671CrossRefPubMedPubMedCentral
24.
go back to reference Parchi P, Cescatti M, Notari S, Schulz-Schaeffer WJ, Capellari S, Giese A et al (2010) Agent strain variation in human prion disease: insights from a molecular and pathological review of the National Institutes of Health series of experimentally transmitted disease. Brain 133:3030–3042CrossRefPubMedPubMedCentral Parchi P, Cescatti M, Notari S, Schulz-Schaeffer WJ, Capellari S, Giese A et al (2010) Agent strain variation in human prion disease: insights from a molecular and pathological review of the National Institutes of Health series of experimentally transmitted disease. Brain 133:3030–3042CrossRefPubMedPubMedCentral
25.
go back to reference Parchi P, de Boni L, Saverioni D, Cohen ML, Ferrer I, Gambetti P et al (2012) Consensus classification of human prion disease histotypes allow reliable identification of molecular subtypes: an inter-rater study among surveillance centres in Europe and USA. Acta Neuropathol 124:517–529CrossRefPubMedPubMedCentral Parchi P, de Boni L, Saverioni D, Cohen ML, Ferrer I, Gambetti P et al (2012) Consensus classification of human prion disease histotypes allow reliable identification of molecular subtypes: an inter-rater study among surveillance centres in Europe and USA. Acta Neuropathol 124:517–529CrossRefPubMedPubMedCentral
26.
go back to reference Peden A, McGuire LI, Appleford NE, Mallinson NE, Wilham JM, Orru CD et al (2012) Sensitive and specific detection of sporadic Creutzfeldt-Jakob disease brain prion protein using real-time quaking-induced conversion. J Gen Virol 93:438–449CrossRefPubMedPubMedCentral Peden A, McGuire LI, Appleford NE, Mallinson NE, Wilham JM, Orru CD et al (2012) Sensitive and specific detection of sporadic Creutzfeldt-Jakob disease brain prion protein using real-time quaking-induced conversion. J Gen Virol 93:438–449CrossRefPubMedPubMedCentral
27.
go back to reference Peden AH, Sarode DP, Mulholland CR, Barria MA, Ritchie DL, Ironside JW et al (2014) The prion protein protease sensitivity, stability and seeding activity in variably protease sensitive prionopathy brain tissue suggests molecular overlaps with sporadic Creutzfeldt-Jakob disease. Acta Neuropathol Commun 2:152CrossRefPubMedPubMedCentral Peden AH, Sarode DP, Mulholland CR, Barria MA, Ritchie DL, Ironside JW et al (2014) The prion protein protease sensitivity, stability and seeding activity in variably protease sensitive prionopathy brain tissue suggests molecular overlaps with sporadic Creutzfeldt-Jakob disease. Acta Neuropathol Commun 2:152CrossRefPubMedPubMedCentral
28.
go back to reference Powell-Jackson J, Weller RO, Kennedy P, Preece MA, Whitcombe EM, Newsom-Davis J (1985) Creutzfeldt-Jakob disease after administration of human growth hormone. Lancet 2:244–246CrossRefPubMed Powell-Jackson J, Weller RO, Kennedy P, Preece MA, Whitcombe EM, Newsom-Davis J (1985) Creutzfeldt-Jakob disease after administration of human growth hormone. Lancet 2:244–246CrossRefPubMed
29.
31.
go back to reference Rudge P, Jaunmuktane Z, Adlard P, Bjurstrom N, Caine D, Lowe J et al (2015) Iatrogenic CJD due to pituitary-derived hormone with genetically determined incubation times of up to 40 years. Brain 138:3386–3399CrossRefPubMedPubMedCentral Rudge P, Jaunmuktane Z, Adlard P, Bjurstrom N, Caine D, Lowe J et al (2015) Iatrogenic CJD due to pituitary-derived hormone with genetically determined incubation times of up to 40 years. Brain 138:3386–3399CrossRefPubMedPubMedCentral
32.
go back to reference Shi S, Mitteregger-Kretzschmar G, Giese A, Kretzschmar HA (2013) Establishing quantitative real-time quaking-induced conversion (qRT-QuIC) for highly sensitive detection and quantification of PrPSc in prion-infected tissues. Acta Neuropathol Commun 1:44CrossRefPubMedPubMedCentral Shi S, Mitteregger-Kretzschmar G, Giese A, Kretzschmar HA (2013) Establishing quantitative real-time quaking-induced conversion (qRT-QuIC) for highly sensitive detection and quantification of PrPSc in prion-infected tissues. Acta Neuropathol Commun 1:44CrossRefPubMedPubMedCentral
33.
go back to reference Swerdlow AJ, Higgins CD, Adlard P, Jones ME, Preece MA (2003) Creutzfeldt-Jakob disease in United Kingdom patients treated with human pituitary growth hormone. Neurology 61:783–791CrossRefPubMed Swerdlow AJ, Higgins CD, Adlard P, Jones ME, Preece MA (2003) Creutzfeldt-Jakob disease in United Kingdom patients treated with human pituitary growth hormone. Neurology 61:783–791CrossRefPubMed
34.
go back to reference Takeuchi A, Kobayashi A, Parchi P, Yamada M, Morita M, Uno S et al (2016) Distinctive properties of plaque-type dura mater graft-associated Creutzfeldt-Jakob disease in cell-protein misfolding cyclic amplification. Lab Invest 96:581–587CrossRefPubMed Takeuchi A, Kobayashi A, Parchi P, Yamada M, Morita M, Uno S et al (2016) Distinctive properties of plaque-type dura mater graft-associated Creutzfeldt-Jakob disease in cell-protein misfolding cyclic amplification. Lab Invest 96:581–587CrossRefPubMed
36.
go back to reference Xiao X, Yuan J, Qing L, Cali I, Mikol J, Delisle MB, et al (2014) Comparative study of prions in iatrogenic and sporadic Creutzfeldt-Jakob disease. J Clin Cell Immunol 5:pii240 Xiao X, Yuan J, Qing L, Cali I, Mikol J, Delisle MB, et al (2014) Comparative study of prions in iatrogenic and sporadic Creutzfeldt-Jakob disease. J Clin Cell Immunol 5:pii240
Metadata
Title
UK Iatrogenic Creutzfeldt–Jakob disease: investigating human prion transmission across genotypic barriers using human tissue-based and molecular approaches
Authors
Diane L. Ritchie
Marcelo A. Barria
Alexander H. Peden
Helen M. Yull
James Kirkpatrick
Peter Adlard
James W. Ironside
Mark W. Head
Publication date
01-04-2017
Publisher
Springer Berlin Heidelberg
Published in
Acta Neuropathologica / Issue 4/2017
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-016-1638-x

Other articles of this Issue 4/2017

Acta Neuropathologica 4/2017 Go to the issue